Gene Therapy Drug Articles & Analysis
19 news found
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded ...
In addition to a variety of experimental animals including mice, rats, rabbits, and monkeys, Ace Therapeutics can assist worldwide clients in constructing custom animal models using techniques such as environmental enrichment, gene editing, dietary modifications, or drug therapies. Moreover, the company can also provide researchers with cardiac ...
They play an essential role in intercellular communication and hold high potential as drug delivery systems due to their natural ability to carry and deliver substances within the body. BOC Sciences' inclusion of exosome drug delivery technologies aims to leverage this potential and enhance their applications in RNA therapeutics. ...
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene ...
The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including gene therapies, throughout the gastrointestinal tract. ...
In recent years, CRISPR technology has significantly promoted the innovation of gene therapy for blood diseases, tumors, genetic diseases, and other diseases, which has become a powerful tool in the field of scientific research. ...
“This clinical data validates the significant potential of our patented platform to deliver therapeutics as varied as gene therapy, virus-like drug conjugates, and small molecules directly to the back of the eye in an office-based, non-surgical procedure. ...
The study (NCT04676048) is expected to assess the one-time gene therapy’s safety and preliminary effectiveness in up to 12 adults with moderate to severe hemophilia A. ...
Compared with traditional drug therapy, gene therapy is to fundamentally control the disease, so it has a very good development prospect, and has received more and more attention and investment from the pharmaceutical industry worldwide. Gene therapy drugs are in clinical trials ...
Zisoulis brings a wealth of experience in drug development in the gene therapy space. Most recently, he was Vice President of Drug Discovery at Locanabio, where he helped develop new RNA-targeting therapeutics. At Mammoth, he will lead the discovery and development of next-generation in vivo gene-editing ...
At CPhI Worldwide 2021, Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics. CPhI 2021 begins with a ...
Suono Bio’s platform technology enables the rapid, targeted delivery of drugs, including gene therapies, for the first time, enabling the use of the right drug in the right patient. ...
This week, Thermo Fisher Scientific will highlight its investments and innovations over the past 12 months across its global pharma services network, which have been focused on areas of accelerated demand including cell and gene therapy, drug product development, biologics manufacturing and clinical supply chain services. ...
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced positive interim safety, protein expression and biomarker data from the ongoing open-label Phase I/II FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) ...
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy ...
Earlier this year, the company announced plans to invest in new capabilities and capacity for biologics, cell and gene therapies and drug product development and commercialization. For example, to support demand for gene therapies, Thermo Fisher will be doubling its viral vector manufacturing capacity with a new ...
Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines Promising cancer gene therapy programme using small interfering RNA (siRNA) Data from in vitro study published in PLOS journal Stratford-upon-Avon, UK, 13 May 2019 – ...
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. ...
ByVybion
Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington's disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation ...
ByVybion